Bluebird Bio has placed its Phase I/II (HGB-206) and Phase III (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukaemia (AML). In line with the clinical study protocols for HGB-206 and HGB-210, the company […]
Menu ≡ ╳ 
